Literature DB >> 20610143

Decreased retinol binding protein 4 concentrations are associated with cholesterol gallstone disease.

Shen-Nien Wang1, Yao-Tsung Yeh, Sen-Teh Wang, Yi-Ling Chen, Shih-Chang Chuang, Chen-Guo Ker, King-Teh Lee.   

Abstract

BACKGROUND/
PURPOSE: Circulating retinol binding protein 4 (RBP4) is associated with a variety of obesity-related diseases. This study investigated whether there were aberrant concentrations of RBP4 in cholesterol gallstone disease.
METHODS: Serum RBP4 levels of 100 cholesterol gallstone patients and 147 healthy controls were measured by enzyme-linked immunosorbent assay and further correlated with clinical and biochemical characteristics, including insulin resistance and renal function. Gallstone specimens were obtained during laparoscopic cholecystectomy and analyzed for their chemical composition using Fourier transform infrared spectroscopy
RESULTS: Significantly lower serum RBP4 levels were found in patients with cholesterol gallstones in comparison with controls (30.57 +/- 13.64 mg/L vs. 41.52 +/- 20.25 mg/L, p<0.001). Lower serum RBP4 levels were also associated with gallstone occurrence (odds ratio = 0.93; 95% confidence interval = 0.88-0.96; p = 0.004). Serum RBP4 levels of all subjects were positively correlated with total cholesterol, triglyceride, creatinine, insulin resistance and albumin, and inversely correlated with aspartate aminotransferase and alanine aminotransferase. In multivariate analysis, cholesterol gallstone formation was significantly associated with a lower serum RBP4 level (odds ratio = 4.2; 95% confidence interval= 1.40-12.57; p = 0.010). RBP4 levels were significantly decreased regardless of renal function in patients with gallstones, but levels increased proportionate to renal dysfunction in people without gallstones.
CONCLUSION: Circulating RBP4 decreases in cholesterol gallstone disease independent of renal function. Further studies are needed to investigate the relationship between liver function and RBP4 levels in these patients. Copyright (c) 2010 Formosan Medical Association & Elsevier. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20610143     DOI: 10.1016/S0929-6646(10)60073-3

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  5 in total

1.  Retinol-binding protein 4 as a risk factor for cholesterol gallstone formation.

Authors:  Tao Han; Diancai Zhang; Zan Fu; Yueming Sun; Wei Yang; Cuimei Yuan
Journal:  Mol Cell Biochem       Date:  2013-02-19       Impact factor: 3.396

2.  Retinol-binding protein 4 and its potential roles in hypercholesterolemia revealed by proteomics.

Authors:  Watcharapong Jugnam-Ang; Supitcha Pannengpetch; Patcharee Isarankura-Na-Ayudhya; Chadinee Thippakorn; Chartchalerm Isarankura-Na-Ayudhya; Ratana Lawung; Virapong Prachayasittiku
Journal:  EXCLI J       Date:  2015-08-28       Impact factor: 4.068

3.  The long non-coding RNA MEG3 plays critical roles in the pathogenesis of cholesterol gallstone.

Authors:  Changlin Qian; Weiqing Qiu; Jie Zhang; Zhiyong Shen; Hua Liu; Yongjie Zhang
Journal:  PeerJ       Date:  2021-02-23       Impact factor: 2.984

4.  Associations between retinol-binding protein 4 and cardiometabolic risk factors and subclinical atherosclerosis in recently postmenopausal women: cross-sectional analyses from the KEEPS study.

Authors:  Gary Huang; Dan Wang; Unab I Khan; Irfan Zeb; JoAnn E Manson; Virginia Miller; Howard N Hodis; Matthew J Budoff; George R Merriam; Mitchell S Harman; Eliot A Brinton; Marcelle I Cedars; Yali Su; Rogerio A Lobo; Frederick Naftolin; Nanette Santoro; Hugh S Taylor; Rachel P Wildman
Journal:  Cardiovasc Diabetol       Date:  2012-05-15       Impact factor: 9.951

5.  Identification of KMU-3, a novel derivative of gallic acid, as an inhibitor of adipogenesis.

Authors:  Yu-Kyoung Park; Jinho Lee; Victor Sukbong Hong; Jong-Soon Choi; Tae-Yoon Lee; Byeong-Churl Jang
Journal:  PLoS One       Date:  2014-10-06       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.